E-LIB Suche - Ergebnisse für: Kater, A. P.

1

Additional booster doses in patients with chronic lymphocyt..:

Campanella, A. ; Capasso, A. ; Heltai, S....
American Journal of Hematology. 99 (2024) 4 - p. 745-750 , 2024

Link: https://doi.org/10.1002/..

2

ESMO Clinical Practice Guideline interim update on new targ..:

Eichhorst, B. ; Ghia, P. ; Niemann, C.U....
Annals of Oncology. , 2024

Link: https://doi.org/10.1016/..

3

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 249-250 , 2023

Link: https://doi.org/10.1002/..

4

EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REF..:

Eichhorst, B. ; Eradat, H. ; Niemann, C. U....
Hematological Oncology. 41 (2023) S2 - p. 828-829 , 2023

Link: https://doi.org/10.1002/..

5

Early-stage measurable residual disease dynamics and IGHV r..:

Hengeveld, P. J. ; Schilperoord-Vermeulen, J. ; van der Klift, M. Y....
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

6

MURANO: Final 7 year follow up and retreatment analysis in ..:

Kater, A. P. ; Harrup, R. ; Kipps, T. J....
Hematological Oncology. 41 (2023) S2 - p. 239-242 , 2023

Link: https://doi.org/10.1002/..

7

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERAT..:

Le Gouill, S. ; Długosz-Danecka, M. ; Rule, S....
HemaSphere. 6 (2022) - p. 1021-1022 , 2022

Link: https://doi.org/10.1097/..

8

P612: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)-DERIVED T-CELLS HA..:

Jacobs, C. F. ; Simon-Molas, H. ; Zelcer, N...
HemaSphere. 6 (2022) - p. 511-512 , 2022

Link: https://doi.org/10.1097/..

9

PB1886: LONG-TERM TRENDS IN THE LOSS OF LIFE EXPECTANCY AFT..:

Van Der Straten, L. ; Maas, C. C. ; Levin, M.-D....
HemaSphere. 6 (2022) - p. 1765-1766 , 2022

Link: https://doi.org/10.1097/..

10

P1170: INCIDENCE, TREATMENT AND OUTCOME OF PATIENTS WITH RI..:

Huisman, F. ; Al-sarayfi, D. ; Bellido, M....
HemaSphere. 6 (2022) - p. 1056-1057 , 2022

Link: https://doi.org/10.1097/..

11

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITU..:

Wu, J. Q. ; Seymour, J. F. ; Eichhorst, B....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERS..:

Hillmen, P. ; Byrd, J. C. ; Ghia, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WIT..:

Amaador, K ; Martens, A. W. J ; de Boer, R...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACT..:

Wang, M. ; Rule, S. ; Zinzani, P. L....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

CLL-092: Phase 3 Trial of Acalabrutinib in Combination with..:

Brown, Jennifer R. ; Eichhorst, Barbara ; Ghia, Paolo...
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) - p. S221-S222 , 2020

Link: https://doi.org/10.1016/..